ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,307.01
-0.27%
Dow Jones
39,671.04
-0.51%
US Dollar vs MXN
16.66839
0.02%
Brent Oil
81.855
0.40%
Bitcoin
69,576.96
0.69%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Noticias

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AZN
FechaHoraFuenteTítuloSímboloCompañía
22/05/202406:00Business WireAstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​NASDAQ:AZNAstraZeneca PLC
21/05/202417:44Business Wireアストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定NASDAQ:AZNAstraZeneca PLC
21/05/202410:37Business WireAstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 anNASDAQ:AZNAstraZeneca PLC
21/05/202410:36Business WireAstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030NASDAQ:AZNAstraZeneca PLC
21/05/202406:18IH Market NewsCalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More NewsNASDAQ:AZNAstraZeneca PLC
21/05/202405:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
21/05/202401:00Business WireAstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030NASDAQ:AZNAstraZeneca PLC
19/05/202416:17Business WireNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary diseaseNASDAQ:AZNAstraZeneca PLC
13/05/202406:16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNASDAQ:AZNAstraZeneca PLC
06/05/202401:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:AZNAstraZeneca PLC
02/05/202406:00Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trialNASDAQ:AZNAstraZeneca PLC
01/05/202406:05Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolioNASDAQ:AZNAstraZeneca PLC
29/04/202406:00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralowNASDAQ:AZNAstraZeneca PLC
25/04/202407:00PR Newswire (US)AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:AZNAstraZeneca PLC
25/04/202406:53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:AZNAstraZeneca PLC
25/04/202406:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:AZNAstraZeneca PLC
25/04/202401:00Business WireQ1 2024 resultsNASDAQ:AZNAstraZeneca PLC
16/04/202406:00Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trialNASDAQ:AZNAstraZeneca PLC
12/04/202406:05IH Market NewsParamount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202406:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202406:00Business WireFASENRA approved for treatment of children aged 6 to 11 with severe asthmaNASDAQ:AZNAstraZeneca PLC
05/04/202422:10Business WireENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid TumorsNASDAQ:AZNAstraZeneca PLC
05/04/202420:43Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumorsNASDAQ:AZNAstraZeneca PLC
05/04/202406:00Business WireIMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trialNASDAQ:AZNAstraZeneca PLC
02/04/202406:00Business WireDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
02/04/202401:00Business WireDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerNASDAQ:AZNAstraZeneca PLC
01/04/202406:00Business WireVOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNHNASDAQ:AZNAstraZeneca PLC
27/03/202405:54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNASDAQ:AZNAstraZeneca PLC
26/03/202406:20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNASDAQ:AZNAstraZeneca PLC
25/03/202406:00Business WireULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)NASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Su Consulta Reciente

NASDAQ
ALNT
Allient
EU
CAFSU
Credit Agricole CIB Fina...
BIT
FUL
Beewize
GATE
SUPERUSDT
SuperFarm
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados